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. To identify the target of these agents we developed biotinylated photoactivatable GSMs. GSM photoprobes did not label the core proteins of the c-secretase complex, but instead labelled the b-amyloid precursor protein (APP), APP carboxy-terminal fragments and amyloid-b peptide in human neuroglioma H4 cells. Substrate labelling was competed by other GSMs, and labelling of an APP c-secretase substrate was more efficient than a Notch substrate. GSM interaction was localized to residues 28-36 of amyloid-b, a region critical for aggregation. We also demonstrate that compounds known to interact with this region of amyloid-b act as GSMs, and some GSMs alter the production of cell-derived amyloid-b oligomers. Furthermore, mutation of the GSM binding site in the APP alters the sensitivity of the substrate to GSMs. These findings indicate that substrate targeting by GSMs mechanistically links two therapeutic actions: alteration in Ab42 production and inhibition of amyloid-b aggregation, which may synergistically reduce amyloid-b deposition in Alzheimer's disease. These data also demonstrate the existence and feasibility of 'substrate targeting' by small-molecule effectors of proteolytic enzymes, which if generally applicable may significantly broaden the current notion of 'druggable' targets 2 .
We previously demonstrated that a subset of non-steroidal antiinflammatory drugs (NSAIDs; that is, ibuprofen and sulindac) are examples of GSMs-agents capable of preferentially lowering Ab42 in vitro and in vivo 3, 4 . A signature of Ab42-lowering GSMs is a reciprocal increase in shorter amyloid-b peptides. Further studies have identified tarenflurbil (formerly named R-flurbiprofen 5 ) as a non-NSAID Ab42-lowering GSM with potential therapeutic application in Alzheimer's disease 3, 6 . In contrast to c-secretase inhibitors, most GSMs do not inhibit c-secretase-mediated release of the intracellular cytoplasmic domains of APP or other c-secretase substrates such as Notch and ErbB4 3, 4 . We have also identified other GSMs that selectively increase Ab42 quantities, similar to mutations in presenilin 1 (PSEN1) and APP which cause familial Alzheimer's disease 7, 8 . Although studies have suggested that GSMs target c-secretase, the mechanism of amyloid-b modulation by GSMs has not been definitively established 3, 9, 10 . We synthesized two GSM derivatives for photoaffinity labelling studies to determine the molecular targets of the GSMs: fenofibratebiotin (Fen-B), a derivative of fenofibrate which is an Ab42-raising GSM, and flurbiprofen-benzophenone-biotin (Flurbi-BpB), a derivative of tarenflurbil which is an Ab42-lowering GSM (Fig. 1a) . Each compound contains benzophenone (a preferred photoactive moiety for protein labelling 11 ) and a biotin tag (for detection and affinity purification), and maintains the activity of the parent GSM ( Supplementary Figs 2 and 3) .
Initial crosslinking of Fen-B (1-100 mM) in lysates from human neuroglioma H4 cells overexpressing APP demonstrated that numerous proteins were labelled but that PSEN1 was not (data not shown). To determine whether this negative result was due to limited sensitivity, we investigated the ability of Fen-B to label a highly purified preparation of active c-secretase 12 . Photolysis of purified c-secretase (Fig. 1b) in the presence of Fen-B (300 mM) followed by precipitation with streptavidin did not label the core components of c-secretase (PSEN1, nicastrin (NCSTN), anterior pharynx-defective 1 (APH1) or presenilin enhancer 2 (PSENEN, also known as PEN2)). Similar studies with biotinylated carprofen 13 , an Ab42-lowering GSM, did not detect labelling of c-secretase (B.S., unpublished data). Having failed to label the subunits of c-secretase, we turned our attention to the remaining member of an active c-secretase 'complex': the substrate itself. We addressed whether a purified, recombinant Flag-tagged c-secretase substrate derived from APP (APP(C100)-Flag, comprising the 99 C-terminal residues of APP plus a methionine at the N terminus, ref. 12) could be labelled by Fen-B and Flurbi-BpB. Photoactivated crosslinking with concentrations of GSM photoprobes spanning the range over which they modulate Ab42 led to increasing quantities of biotinylated APP(C100)-Flag (Fig. 1c) . Labelling of APP(C100)-Flag by Fen-B was competed by Ab42-raising and -lowering GSMs (Fig. 1d) ; however, non-GSM NSAIDs (aspirin, naproxen) did not compete (data not shown). The sulphone derivative of the GSM sulindac, which does not affect Ab42 levels, did not compete for labelling, showing that small structural features influence the ability to modulate amyloid-b and compete for labelling of APP C-terminal fragments (CTFs; Fig. 1d ). These results indicate that binding of GSMs to the APP substrate could mediate their ability to shift the location of c-secretase cleavage.
Next, we addressed whether the interaction between APP CTF and GSMs could be detected in cells. Direct exposure of H4 cells to ultraviolet and photoprobes was toxic ( Supplementary Fig. 3) ; therefore, crosslinking of Fen-B and Flurbi-BpB was examined in solubilized membrane fractions from human neuroglioma H4 cells enriched for active c-secretase and substrates (APP CTFs 83 and 99) this protein as a-secretase-derived APP CTF (CTF83) on the basis of molecular weight, increased expression in APP-transfected cells and immunoreactivity with an APP C-terminal antibody ( Fig. 1e and Supplementary Fig. 2 ), but not an antibody against Ab1-16 which would recognize b-secretase-derived APP CTF (CTF99; not shown). Labelling of APP CTF was photoactivation dependent (Fig. 1e) and no binding to PSEN1 CTF, PSEN1 amino-terminal fragment (NTF) or nicastrin was observed in these experiments (data not shown). These data demonstrate that labelling of APP CTF by GSMs can occur in cellular membrane fractions, providing further evidence that this interaction may be responsible for the modulation of amyloid-b production.
GSMs have been reported to modulate the site of c-secretase cleavage in other substrates such as Notch 14 . We previously reported that APP is more sensitive than Notch to shifts in the location of c-cleavage induced by GSMs 15 . Consistent with the differential sensitivity of Notch to GSMs that we observe, we find that whereas Fen-B does label a recombinant substrate derived from mouse Notch (Notch(C100)-Flag), this reaction is less efficient than Fen-B labelling of the APP(C100)-Flag (Fig. 1f) . Furthermore, the presence of purified c-secretase does not prevent labelling of either substrate by Fen-B ( Supplementary Fig. 4 ). These data suggest that a differential affinity of the GSM Fen-B occurs between APP and other c-secretase substrates such as Notch, and further link substrate targeting to the GSM properties of these compounds.
Initial mapping experiments showed that Fen-B did not label the last 50 amino acids of APP (APP intracellular domain, CTF-c), raising the possibility that it was binding the amyloid-b region of APP ( Supplementary Fig. 5 ). To define precisely the binding site of GSMs, C-terminal-truncated versions of amyloid-b were irradiated in the presence of Fen-B. Fen-B efficiently labelled Ab1-40 and Ab1-36 but did not label Ab1-28 ( Fig. 2a) , suggesting that a minimal binding site on APP(C100)-Flag corresponds to residues 29-36 (GAIIGLMV) of amyloid-b (Fig. 2a) . Ab1-36 can also be labelled by Flurbi-BpB (Fig. 2b) , and both GSMs can label Flag-tagged Ab25-36 (Fig. 2c) . These residues represent the start of the predicted APP transmembrane domain (625-632 of APP695) that lies within the membrane; however, this region of APP is accessible to small molecules 16 . Because the putative binding region of GSMs is also found in full-length APP we looked for labelling of both APP fragments in cells. Using microsomal membrane fractions from H4 cells expressing wild-type APP, we observed that both Fen-B and Flurbi-BpB labelled full-length APP and APP CTFs ( Supplementary Fig. 6 ). Labelling of APP CTF and APP by GSM photoprobes was competed by both Ab28-36 and structurally diverse is competed by Ab42-lowering and -raising GSMs (100 mM) but not by sulindac sulphone, a non-GSM NSAID. Data are presented as percentage control 6 s.e.m., n 5 2. Asterisk, P , 0.05; two asterisks, P , 0.01; ANOVA with Dunnett's posthoc analysis. e, GSM photoprobes label APP CTF from cells. CHAPSO solubilized membrane fractions from H4 APP-CTF-alkaline phosphatase cells were crosslinked with Fen-B and Flurbi-BpB (50 mM) and analysed by immunoprecipitation with streptavidin and immunblotting for APP (antibody CT20). Both GSMs label a fragment of APP that co-migrates with APP(C83). UV, ultraviolet. f, A GSM photoprobe preferentially labels a recombinant APP substrate (APP(C100)-Flag; left panel) relative to Notch (Notch(C100)-Flag; right panel). Samples were analysed by western blotting for incorporation of Fen-B. Green, biotin; red, Flag; yellow, dual reactivity; LiCor Odyssey.
GSMs, further supporting the specificity of this interaction (Supplementary Fig. 7 ). Taken together, these data provide evidence that the minimal binding site for raising and lowering GSM is Ab28-36. Notably, this region of Ab and APP is important for amyloid-b aggregation 17 and has been implicated as a binding site for amyloid-b aggregation inhibitors 18 . Furthermore, we 19 and others 20 have shown that mutations in this region of APP can drastically change the spectrum of amyloid-b species, supporting the notion that binding of GSMs to substrate in this region could alter c-secretase cleavage. Indeed, we find that a peptide (I1, NH 2 -FEGKF-CONH 2 ) known to bind to this region of amyloid-b acts as a GSM 17 . I1 elevated Ab42 production without lowering total amyloid-b amounts, similar to fenofibrate (Fig. 2d) .
If GSMs target the amyloid-b region of APP CTF, then any compound that binds to Ab is a potential GSM. To test this possibility, we examined 15 compounds for GSM activity that had previously been reported as amyloid-b binding compounds, amyloid-b aggregation inhibitors or amyloid-b binding agents (Supplementary Fig. 8 ). Six of these compounds did not act as GSMs (for example, melatonin, BTA-1), but the remainder all showed GSM activity. These included two Ab42-raising (the kinase inhibitor DAPH (4,5-dianilinophthalimide) and the calmodulin inhibitor, calmidazolium) and seven Ab42-lowering GSMs (for example, the amyloid dye X-34 (1,4-bis(3-carboxy-4-hydroxyphenylethenyl)-benzene) and the hydrophobic probe Bis-ANS (4,49-dianilino-1,19-binaphthyl-5,59-disulphonic acid); Fig. 3a ). Immunoprecipitation and mass spectrometry analysis showed that the lowering of Ab42 by X-34 and chrysamine G was accompanied by increased amounts of shorter amyloid-b, a characteristic signature of Ab42-lowering GSMs (Supplementary Fig. 9 ). In cell-free c-secretase assays, Congo red and chrysamine G lowered Ab42 selectively, demonstrating that they are bona fide GSMs (Supplementary Fig. 10 ).
We focused on X-34 to characterize its GSM properties further. Cellular dose-response studies showed that X-34 lowered Ab42 (effector concentration for half-maximum response, EC 50 , 13.7 mM) and Ab40 at higher concentrations (EC 50 60.7 mM), but did not decrease total amyloid-b amounts (Fig. 3b) . X-34 competes for binding of APP(C100)-Flag by Fen-B and Flurbi-BpB (Fig. 3c) . We also found that X-34 fluorescence increased when incubated with monomeric Ab42. This allowed saturation binding experiments to determine that X-34 bound to Ab42 with a dissociation constant (K d (Supplementary Fig. 11) . Thus, the affinity of X-34 for a peptide containing the putative GSM binding site is similar to concentrations at which it acts as a GSM in cells. Finally, we addressed whether X-34 modulated Ab42 amounts in an APP transgenic mouse (Tg2576). We found that X-34 (100 mg kg
21
) decreased soluble Ab42 (35%, P , 0.01) in the brains of Tg2576 mice with no effects on Ab40 (Fig. 3d) . Tarenflurbil (50 mg kg
) in the same paradigm also lowered Ab42 (25%, P , 0.05) without a decrease in Ab40 (123%, Fig. 3d) . Collectively, these observations support the hypothesis that GSMs interact with substrate. Furthermore, the data show that selecting compounds on the basis of their ability to bind amyloid-b and APP is an efficient strategy to identify GSMs and suggest that screening compounds for binding to amyloid-b should be a simple and useful method to discover previously unknown GSMs.
On the basis of our previous findings which showed that GSMs bind a region in APP and amyloid-b that is involved in fibrilization 17 , we reasoned that GSMs may also affect the aggregation of amyloid-b. Previous studies have shown that compounds with GSM activity, including certain NSAIDs 21 , Congo red 22 and Bis-ANS 23 , can inhibit the in vitro aggregation of synthetic amyloid-b. However, it is unknown if GSMs influence the concentration of secreted amyloid-b oligomers, such as those released by Chinese hamster ovary (CHO) cells expressing the APP V717F mutation (referred to as 7PA2 cells), which alter long-term potentiation and perturb the memory of learned behaviour when injected into rat brain 24, 25 . To address this question we treated 7PA2 cells with two Ab42-raising GSMs and a novel Ab42-lowering GSM (Supplementary Fig. 12 ). Fenofibrate and FT-1 (ref. 7) increased amounts of Ab42 whereas FT-9 lowered Ab42, but all three GSMs decreased amounts of amyloid-b dimers and trimers. Extended dose experiments with fenofibrate and FT-9 show a consistent decrease in amyloid-b oligomers at doses where total amyloid-b amounts are not altered (Supplementary Fig. 12 ). In contrast to increased amyloid-b oligomer formation, when CHO cells are genetically manipulated to increase Ab42 production by co-expression of APP and FAD-linked mutant PSEN1 proteins, we find that both Ab42-lowering and -raising GSMs decrease oligomer formation 26 . Notably, amyloid-b oligomers in 7PA2 and neuronal cells are generated intracellularly before secretion 27 . Therefore, the finding that GSMs shift amyloid-b cleavage by targeting a region of substrate present in the amyloid-b cleavage product provides a mechanistic link between GSM activity and general anti-amyloid-b aggregation effects and also suggests that the binding of GSM to substrate and inhibition of amyloid-b oligomerization can occur in the same cellular compartment.
Our data suggest that mutation of the GSM binding site in APP should alter sensitivity to GSMs. To test this hypothesis we exchanged a portion of the GSM binding site in APP with the analogous region of human NOTCH (Fig. 4a, b and Supplementary Fig. 13 ). We used this chimaeric construct because in our hands the NOTCH transmembrane domain (TMD) is resistant to GSM effects 15 . The APP-NOTCH TMD construct produces a spectrum of chimaeric amyloid-b species in conditioned cell media (Supplementary Fig. 13 ). Although the molecular weight and abundance of each chimaeric peptide differs from amyloid-b peptides from APP, the main species produced from the APP-NOTCH TMD construct have identical C termini to Ab1-40 and Ab1-42, and can be quantified by enzyme-linked immunosorbent assays (ELISAs; Supplementary Fig. 13 ). We therefore examined the relative sensitivity to GSMs of APP-NOTCH TMD versus APP in stably transfected cells. Cleavage of APP-NOTCH TMD was not significantly affected by either an Ab42-lowering GSM or an Ab42-raising GSM but remained sensitive to inhibition by treatment with the c-secretase inhibitor L-685458 (Fig. 4a, b and Supplementary Fig. 13 ). Thus, exchange of residues in the putative binding site render the substrate much less sensitive to GSMs.
Several explanations for the GSM activity of NSAIDs have been proposed. It has recently been hypothesized that NSAIDs alter dimerization of APP 20 . Although plausible, there is no conclusive evidence that an APP dimer is the substrate for c-secretase, and it is difficult to account for both Ab42-raising and -lowering properties of structurally related GSMs with this model. Other studies propose that GSMs lower Ab42 by shifting presenilin conformation through allosteric binding 28, 29 . Our data implicating substrate targeting by GSMs is compatible with these previous findings (Supplementary Discussion). It is also possible that GSMs shift cleavage by changing the position of APP CTF in the plane of the membrane leading to shifts in the amyloid-b fragments produced 19 . This model is attractive as it accounts for the difference between the classes of GSMs: Ab42-raising GSMs would 'pull' the substrate out of the membrane, whereas Ab42-lowering GSMs allow the substrate to 'sink' further into the membrane.
Given the likelihood that GSMs exist that directly target the enzyme, we believe it is appropriate to refer to the GSMs we have identified as substrate-targeting GSMs. Substrate-targeting GSMs can, in theory, have two therapeutic consequences-alteration in Ab42 production and inhibition of amyloid-b aggregation-that might synergistically benefit the Alzheimer's disease phenotype (Supplementary Fig. 1 ). Future substrate-targeting GSMs could be developed that optimize the selective Ab42-lowering and antiaggregation properties. These data may also explain why substratetargeting GSMs that raise Ab42 may not be as risky as our data initially implied 7 : although they raise Ab42, they may also inhibit amyloid-b aggregation. Finally, these data demonstrate a new means of modulating intramembrane cleaving proteases through substrate-binding small molecules, which may have broad therapeutic applications 2, 30 .
METHODS SUMMARY
Photoaffinity labelling. All experiments used the following general protocol. Samples (recombinant or synthetic peptides, cell lysates and membrane preparations) were exposed in borosilicate test tubes to ultraviolet light (350 nm) in a Rayonet Photoreactor R100 (RPR-3500 lamps, Southern New England Ultra Violet Company) in a cold room (4 uC) for 30 min or as otherwise noted. Crosslinked samples were analysed by ELISA for biotin incorporation, or analysed directly by SDS-PAGE (Criterion-XT, Bio-Rad), or after precipitation with streptavidin ultralink plus beads (Pierce). After immunblotting, proteins were detected using chemiluminesence (ECL Plus, GE Healthcare) or near-infrared fluorescence (LiCor Odyssey). Full-length APP and APP CTFs (CTF83, CTF99) were detected with CT20, a rabbit polyclonal antibody against the C terminus of APP. Biotin was detected with an affinity-purified rabbit polyclonal antibody (Bethyl). Cell-based screens for amyloid-b modulation. Human H4 neuroglioma cells (American Type Culture Collection, ATCC) expressing wild-type APP695 protein or CTF105 fused to secreted alkaline phosphatase which is efficiently processed to APP CTFs (CTF83, CTF99) and produce high levels of amyloid-b, were used for the cell-based screens as previously described containing 1% fetal bovine serum. Compounds were dissolved in dimethylsulphoxide (DMSO; 0.5% final concentration) and diluted 200-fold. Media was analysed for various amyloid-b species (40, 42 and total) using ELISAs as described below and previously 7 . The EC 50 values for changes in amyloid-b species were calculated by fitting sigmoid dose-response curves using nonlinear regression in Prism (GraphPad) and are shown as values 6 s.e.m. Statistical analysis. Data are presented as either percentage control or mean 6 s.e.m. Results were analysed using Prism (Graph Pad) with t-tests or one-way analysis of variance analyses (ANOVAs) with Dunnett's post-hoc correction for comparison of multiple samples to a control. Statistical significance is shown as P , 0.05 (one asterisk), P , 0.01 (two asterisks) or P , 0.001 (three asterisks).
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
